Though the ACEi and ARB are commonly used in the management of CVDs (hypertension, coronary artery disease, congestive heart failure) and diabetes, there are conflicting data from studies (13, 15, 16) demonstrating an increase or having minimal effect on ACE2 levels (25–29). This evidence concerns the gene ACE2 and diabetes mellitus.